Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Iniparib Clear all

Conditions: Breast Cancer
Interventions: gemcitabine/carboplatin, Iniparib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 519 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 102
States / cities: Birmingham, Alabama • Sedona, Arizona • Jonesboro, Arkansas + 98 more

Conditions: Triple Negative Breast Cancer
Interventions: gemcitabine plus carboplatin plus BSI-201; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Stanford, California • Philadelphia, Pennsylvania

Conditions: Solid Tumors
Interventions: Iniparib (SAR240550/BSI-201), Carboplatin, Doxorubicin HCL liposome injection, Gemcitabine, Irinotecan, Paclitaxel, Topotecan; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 29
States / cities: Birmingham, Alabama • Santa Maria, California • Vallejo, California + 25 more

Conditions: Ovarian Cancer
Interventions: BSI-201; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: gemcitabine/carboplatin, iniparib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 18
States / cities: Birmingham, Alabama • Denver, Colorado • Torrington, Connecticut + 15 more

Conditions: Uterine Carcinosarcoma
Interventions: paclitaxel, carboplatin, BSI-201 (Iniparib); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 40
States / cities: Aurora, Colorado • Englewood, Colorado • New Britain, Connecticut + 34 more

Conditions: Ovarian Cancer
Interventions: BSI-201; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neoplasm Malignant
Interventions: Iniparib (SAR240550-BSI-201), Gemcitabine, Carboplatin, Placlitaxel, Pegylated liposomal doxorubicin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 6
States / cities: Scottsdale, Arizona • Los Angeles, California • Augusta, Georgia + 3 more

Conditions: Primary Peritoneal Cancer, Advanced Epithelial Ovarian Cancer
Interventions: Iniparib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Tumors
Interventions: BSI-201 (iniparib), irinotecan; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 3
States / cities: New Haven, Connecticut • Houston, Texas • San Antonio, Texas

Conditions: Glioblastoma
Interventions: bsi-201 plus temozolomide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 8
States / cities: Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more

Conditions: Advanced Solid Tumors
Interventions: Iniparib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Tumors
Interventions: bsi-201 + topotecan, bsi-201 + temozolomide, bsi-201 + gemcitabine, bsi-201 + carboplatin/paclitaxel; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 6
States / cities: New Haven, Connecticut • Detroit, Michigan • New York, New York + 3 more

Conditions: Estrogen Receptor Negative (ER-Negative) Breast Cancer, Progesterone Receptor Negative (PR-Negative) Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer, Brain Metastases
Interventions: INIPARIB + irinotecan; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 13
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 10 more

Conditions: Squamous Cell Lung Cancer
Interventions: gemcitabine/carboplatin, gemcitabine/carboplatin plus Iniparib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 67
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 61 more

Search by objective public record fields.

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors

Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma

An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)

A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)